{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:40:14Z","timestamp":1792402814853,"version":"4.4.0"},"reference-count":12,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"unspecified","delay-in-days":291,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Technol Assess Health Care"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>The use of artificial intelligence (AI) in health technology assessment (HTA) is rapidly emerging and evolving worldwide (1;2). While many may tout the potential of AI to enhance efficiency, accuracy, and speed of HTA, these technologies also present risks, concerns, and practical challenges that may limit responsible, ethical, and effective deployment. The 2025 HTAi Global Policy Forum (GPF) brought forward key themes regarding the use of AI in HTA, such as trust, human agency, and risk-based approaches (3). Others have also discussed the policy considerations of AI in HTA (4;5).<\/jats:p>","DOI":"10.1017\/s0266462326104292","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:45:42Z","timestamp":1792399542000},"source":"Crossref","is-referenced-by-count":0,"title":["Dialogue on the use of artificial intelligence in health technology assessment: building a community of practice, transparency, and trust"],"prefix":"10.1017","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1222-6795","authenticated-orcid":false,"given":"Eon","family":"Ting","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yc4wc47","id-type":"ROR","asserted-by":"publisher"}],"name":"HTAi"},{"id":[{"id":"https:\/\/ror.org\/04n8fbz89","id-type":"ROR","asserted-by":"publisher"}],"name":"AstraZeneca Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mittmann","sequence":"additional","affiliation":[{"name":"Canada\u2019s Drug Agency (CDA-AMC)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayath","family":"Janoudi","sequence":"additional","affiliation":[{"name":"Loon Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Kim","sequence":"additional","affiliation":[{"name":"Trajectory Labs"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"S0266462326104292_r3","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462325103395"},{"key":"S0266462326104292_r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.09.008"},{"key":"S0266462326104292_r8","unstructured":"8. Use of Artificial Intelligence Methods to Generate Real-World Evidence Submitted to Canada\u2019s Drug Agency for HTA. July 2026. Available from: https:\/\/www.cda-amc.ca\/use-artificial-intelligence-methods-generate-real-world-evidence-submitted-canadas-drug-agency-hta."},{"key":"S0266462326104292_r4","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462326103560"},{"key":"S0266462326104292_r9","unstructured":"9. IQWiG\u2019s 3rd Information Retrieval Meeting. Available from: https:\/\/www.iqwig.de\/en\/about-us\/events\/information-retrieval-meeting\/."},{"key":"S0266462326104292_r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.1261"},{"key":"S0266462326104292_r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2026.101658"},{"key":"S0266462326104292_r12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-026-10265-5"},{"key":"S0266462326104292_r6","unstructured":"6. Canada\u2019s Drug Agency. Position Statement on the Use of Artificial Intelligence in the Generation and Reporting of Evidence. April 2025. Available from: https:\/\/www.cda-amc.ca\/sites\/default\/files\/MG%20Methods\/Position_Statement_AI_Renumbered.pdf."},{"key":"S0266462326104292_r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.3846"},{"key":"S0266462326104292_r7","unstructured":"7. Use of AI in Evidence Generation: NICE Position Statement. August 2024. Available from: https:\/\/www.nice.org.uk\/guidance\/ecd11\/resources\/use-of-ai-in-evidence-generation-nice-position-statement-pdf-40464268944325."},{"key":"S0266462326104292_r11","unstructured":"11. AI Security Institute (UK). Frontier AI Trends Report. London: AISI; 2025 Dec 18 [cited 2026 Apr 4]. Available from: https:\/\/www.aisi.gov.uk\/frontier-ai-trends-report."}],"container-title":["International Journal of Technology Assessment in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0266462326104292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:45:46Z","timestamp":1792399546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0266462326104292\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"alternative-id":["S0266462326104292"],"URL":"https:\/\/doi.org\/10.1017\/s0266462326104292","relation":{},"ISSN":["0266-4623","1471-6348"],"issn-type":[{"value":"0266-4623","type":"print"},{"value":"1471-6348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"e95"}}